Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients

ABSTRACT

To evaluate treatment outcomes following radioactive iodine (RAI) treatment with a cumulative dose of ≥600 mCi in differentiated thyroid carcinoma (DTC) patients, a retrospective review of medical records was done in 176 DTC patients with a cumulative dose of 600 mCi from January 1993 to December 2013. All patients were followed up for at least 2 years after receiving 600 mCi of I-131 treatment. Remission criteria were no clinical and imaging evidence of disease and low serum thyroglobulin levels during thyroid-stimulating hormone suppression of <0.2 ng/ml or of <1 ng/ml after stimulation in the absence of interfering antibodies. A total of 176 patients were included in the study: 137 – papillary thyroid cancer, 29 – follicular thyroid cancer, 9 – mixed papillary and follicular thyroid cancer, and 1 – Hurthle cell carcinoma. Most of the patients (118, 67%) had locoregional metastasis, whereas 48 patients (27%) had distant metastases at presentation. The median cumulative dose was 900 mCi (range: 600–2200 mCi). The mean follow-up period was 82.84 ± 42.41 months. Only 16 patients (9.1%) met remission criteria at the end of treatment. The rest of patients (160, 90.9%) were not remitted: stable disease in 94 (53.4%), at least 1 metastasis without I-131 uptake in 34 (19.3%), progressive disease in 21 (11.9%), and death during the whole follow-up period in 11 (6.3%). Two patients (1.1%) developed second primary malignancy. Eighteen cases were suspected of bone marrow suppression (14 cases [7.9%] had anemia and 5 cases [2.8%] had neutropenia). Seven patients (3.9%) developed permanent salivary gland dysfunction. Although the complications after receiving RAI treatment with a cumulative dose of ≥600 mCi were low and not severe, the patients with remission were in <10%. Our study suggests that the decision to administer further treatments should be made on an individual basis because beneficial effects may be controversial.

Keywords: 600 mCi, cumulative dose, differentiated thyroid cancer, radioiodine therapy

INTRODUCTION

Distant metastases occur in <10% of patients with papillary and follicular carcinoma but represent the most frequent cause of thyroid cancer-related death. Treatment of distant metastasis (DM) patients is based on radioiodine and locoregional therapies. One-third of DM patients have no I-131 uptake and die because of radioiodine refractory (RR).[1] According to the American Thyroid Association (ATA) 2015, radioiodine refractory is classified in four ways: (i) the malignant/metastatic tissue does not ever concentrate RAI, (ii) the tumor tissue loses the ability to concentrate RAI after previous evidence of RAI-avid disease, (iii) RAI is concentrated in some lesions but not in the others, and (iv) metastatic disease progresses despite significant concentration of RAI.[2] These conditions have led to the development of targeted therapy and tyrosine kinase inhibitors, which have shown clinical activity in Phase III trials.[3,4] However, these drugs have significant...
toxicities. The previous study of Durante et al.\(^\text{[5]}\) revealed that most remission is obtained with cumulative activity equal to or lower than 600 mCi (22 GBq). The cumulative activities of I-131 larger than 600 mCi are associated with an increased risk of cancer and leukemia. The aim of our study was to study the outcomes and complications in differentiated thyroid carcinoma (DTC) patients who received RAI treatment with a cumulative dose exceeding or equal to 600 mCi.

**MATERIALS AND METHODS**

**Patients**

A retrospective study of DTC patients who received RAI treatment with a cumulative dose exceeding or equal to 600 mCi in the Division of Nuclear Medicine, Faculty of Medicine Siriraj Hospital, from January 1993 to December 2013 was performed. Each patient was reclassified in accordance with the seventh edition (AJCC 2009) of the TNM staging system for DTC. The 2009 ATA initial risk stratification system was used in evaluation of the risk of recurrence at initiation in each patient (low-risk patients were defined as having intrathyroidal DTC with no evidence of extrathyroidal extension, vascular invasion, or metastases; intermediate-risk patients demonstrated either microscopic extrathyroidal extension, cervical node metastases, RAI-avid disease in the neck outside the thyroid bed, vascular invasion, or aggressive tumor histology; high-risk patients had gross extrathyroidal extension, incomplete tumor resection, distant metastases, or inappropriate post-operative serum thyroglobulin (Tg) values). From the medical folder, age at diagnosis, gender, histopathological type, tumor invasion, radioiodine uptake of postoperative thyroid remnant, radioiodine doses, follow-up period, and outcome of treatment after receiving RAI treatment with a cumulative dose exceeding or equal to 600 mCi were recorded. Patients who were lost to follow-up or died within the first 2 years were excluded. The study was approved by Siriraj Ethics Committee for Human Experiment for retrospective reviews of patient medical records, and the need for informed consent was waived (COA no. Si 106/2015). The patient characteristics are described in Table 1.

**Outcome of treatment**

All patients were followed up for at least 2 years (mean follow-up period was 82.84 ± 42.41 months). Follow-up included whole-body scan (WBS) after RAI treatment and other imaging modalities such as ultrasound (US), computed tomography (CT), or magnetic resonance imaging, and subsequent thyroid-stimulating hormone (TSH), Tg, and Tg antibody (TgAb) measurements were used for detection of metastatic site. Using these, parameter status on follow-up was classified as remission and nonremission.

**Table 1: Baseline demographic and clinical characteristics (n=176)**

| Characteristics                                  | n (%)   |
|--------------------------------------------------|---------|
| Gender (female)                                  | 116 (65.9) |
| Age at diagnosis (years), mean±SD                | 43.22±17.68 |
| 24-h I-131 uptake, median (range) (%)             | 3.3 (0.2-35.1) |
| Histologic cell type                             |         |
| PTC                                              | 137 (77.8) |
| FTC                                              | 29 (16.5) |
| Mixed papillary and follicular cell carcinoma    | 9 (5.1)  |
| Hurthle cell carcinoma                           | 1 (0.6)  |
| Metastasis                                       |         |
| No                                               | 10 (5.7)  |
| Locoregional metastasis                          | 118 (67.0) |
| Distant metastasis (mediastinal node, lung, and bone metastasis) | 48 (27.3) |
| Total I-131 dose, median (range) (mCi)            | 900 (600-2200) |
| Follow-up period, mean±SD (months)               | 82.84±42.41 |

PTC: Papillary thyroid carcinoma, FTC: Follicular cell carcinoma, SD: Standard deviation

Remission was defined according to:

1. No clinical evidence of disease
2. No imaging evidence of tumor by RAI imaging (no uptake at thyroid bed and no uptake outside the thyroid bed on posttreatment WBS and no imaging evidence of tumor on a recent diagnostic or posttreatment WBS) and/or neck US. The images were interpreted by an experienced nuclear medicine physician and a diagnostic radiologist
3. Low serum Tg levels during TSH suppression (<0.2 ng/ml) or after stimulation (<1 ng/ml) without interfering TgAb (<40 IU/mL).

Nonremission was defined as three groups:

a. Stable disease (SD) was classified as unaltered Tg levels, persistent uptake in the previous foci without progression or new metastatic foci

b. Progressive disease (PD) was established as increasing consecutive Tg levels and/or detection of new metastatic foci

c. At least 1 metastasis without I-131 uptake.

Complications from radioiodine treatment were described as:

1. Second primary malignancy (SPM) was clarified as solid or hematologic malignancies that occurred after receiving a cumulative dose exceeding or equal to 600 mCi of I-131. Histological results were obtained for all SPMs to exclude the possibility of metastases

2. Bone marrow suppression was clarified as abnormal of any series of complete blood count on the follow-up period after receiving a cumulative dose exceeding or equal to 600 mCi of I-131. The bone marrow suppression
was classified according to the WHO classification as described below:

- **Neutropenia** is diagnosed if absolute neutrophil count (ANC) < 1,500 cell/mm³
  - Mild neutropenia: ANC 1000–1500 cell/mm³
  - Moderate neutropenia: ANC 500–1000 cell/mm³
  - Severe neutropenia: ANC < 500 cell/mm³
- **Anemia** is diagnosed if hemoglobin (Hb) < 11 g/ml
  - Grade 1 (mild): Hb 9.5–10.9 g/ml
  - Grade 2 (moderate): Hb 8.0–9.4 g/ml
  - Grade 3 (serious): Hb 6.5–7.9 g/ml
  - Grade 4 (life-threatening): Hb < 6.5 g/ml
- **Thrombocytopenia** is diagnosed if platelet count < 100,000/µl

3. Salivary gland dysfunction was clarified as dry mouth, lack of taste, or sialadenitis that patient complained as shown in the medical record on the follow-up after radioiodine treatment. Sialadenitis was clinically diagnosed by swelling in the region of major salivary glands with or without pain with spontaneous resolution and without clinical signs of bacterial or viral infection.

**Statistical analysis**

Continuous variables were presented as mean and standard deviation. Categorical variables were presented as counts with percentage. \( P < 0.05 \) was considered statistically significant. Remission outcomes were analyzed using multiple logistic regression for univariate and multivariate analyses. All analyses were conducted using the SPSS software (version 22.0, IBM Corporation, Armonk, NY, USA).

**RESULTS**

Total number of DTC patients referred to the Division of Nuclear Medicine, Faculty of Medicine Siriraj Hospital, during period January 1993 up to December 2013. Among the 227 DTC patients who received a cumulative dose of ≥600 mCi of I-131, 51 patients were excluded due to lost to follow-up within the first 2 years. Then, 176 patients were enrolled in the study (116 women, mean age: 43.22 ± 17.68 years, range: 9–85 years). The total therapeutic dose ranged from 600 to 2200 mCi. The most common primary tumor histology type was papillary thyroid carcinoma in 137 cases (77.8%). The mean follow-up period was 82.84 ± 42.41 months. Patients and outcomes following I-131 treatment with a cumulative dose exceeding or equal to 600 mCi on the last follow-up are described in Figure 1.

**Remission**

Sixteen patients (9.1%) were diagnosed as being disease free at the end of the follow-up period (12 females with mean age at diagnosis of remission cases of 41.1 ± 16.5 years, mean total therapeutic dose of 795.6 ± 136.4 mCi, mean 24-h I-131 uptake of 3.5% ± 2.4%). Low, intermediate, and high risks of recurrent disease were observed in 5, 10, and 1 case, respectively. The mean period of follow-up was 92.8 ± 35.7 months, as described in Table 2. The univariate and multivariate analyses of significant prognostic factor comparison between the remission and nonremission groups are described in Table 3.

**Nonremission**

There were 160 nonremission cases (105 females with mean age at diagnosis of 43.4 ± 17.9 ng/ml, mean total therapeutic dose of 944.01 ± 236.9 mCi, mean 24-h I-131 uptake of 5.2% ± 5.6%). Low, intermediate, and high risks of recurrent disease were observed in 6, 107, and 47 cases, respectively. The mean period of follow-up was 83.7 ± 43.6 months. Ninety-four cases (53.4%) had SD, 34 (19.3%) had at least 1 metastasis without I-131 uptake, and 21 (11.9%) had PD. Death was found in 11 cases (6.3%), 1 died from pneumonia sepsis, 1 case was secondary malignancy related (non-Hodgkin lymphoma [NHL]), and the rest 9 cases died from an unknown cause. There was no significant difference in the mean survival time of death group (73.5 ± 39.7 months) and alive group (84.9 ± 42.7 months), \( P = 0.39 \).

Among the 160 cases of nonremission cases, DM was found in 117 patients (73.1%), including 34 cases of bone, 32 cases within lungs, and 51 cases within mediastinum. Locoregional metastasis was found in 23 cases.

**Complications**

There were 2 patients (1.1%) of SPM, 18 patients (10.2%) of
suspected bone marrow suppression, and 7 patients (3.9%) of salivary gland dysfunction.

**Second primary malignancy**

Two of 176 patients developed SPM following I-131 treatment with a cumulative dose exceeding or equal to 600 mCi. These included 1 case of NHL and 1 case of invasive ductal carcinoma of the breast. The first case was a 65-year-old man with PTC and cervical lymph node (LN) metastasis who was diagnosed with NHL 20 months after the cumulative activity of I-131 of 600 mCi. He presented with abdominal pain and gastric ulcer, as seen on the gastroscopy. His pathological report from external structures.

| Patient number | Age at diagnosis | Gender | 24-h I-131 uptake before RAI Rx | Diagnosis (site of metastasis) | Risk of recurrence (at initiation) | Total dose (mCi) | F/U period (months) | Comments |
|----------------|------------------|--------|---------------------------------|---------------------------------|----------------------------------|-----------------|-------------------|----------|
| 1              | 67               | Male   | 1.06                            | PTC                             | Low                              | 600             | 77                | Persistent uptake at thyroid bed since the second dose |
| 2              | 22               | Female | 2.3                             | PTC                             | Low                              | 810             | (113)             | Persistent uptake at thyroid bed since the first dose |
| 3              | 41               | Female | 7.9                             | Mixed PTC and FTC               | Low                              | 710             | (199)             |                      |
| 4              | 15               | Male   | 2.37                            | FTC                             | Low                              | 930             | (37)              |                      |
| 5              | 37               | Female | 3.5                             | FTC                             | Low                              | 980             | (114)             |                      |
| 6              | 26               | Female | 6.5                             | PTC (CLN)                       | Intermediate                     | 900             | 102               |                      |
| 7              | 30               | Male   | 2.9                             | PTC (CLN)                       | Intermediate                     | 930             | 158               |                      |
| 8              | 33               | Female | 1                               | PTC (CLN)                       | Intermediate                     | 600             | 89                |                      |
| 9              | 37               | Female | 2.37                            | PTC (CLN)                       | Intermediate                     | 800             | 47                |                      |
| 10             | 60               | Female | 2.5                             | PTC (CLN)                       | Intermediate                     | 800             | 75                |                      |
| 11             | 70               | Female | 7.11                            | PTC with vascular and capsular invasion | Intermediate | 750             | 99                |                      |
| 12             | 63               | Female | 1.66                            | PTC (CLN)                       | Intermediate                     | 600             | 97                |                      |
| 13             | 37               | Female | 6.5                             | PTC (CLN)                       | Intermediate                     | 1100            | 102               |                      |
| 14             | 36               | Female | 1.57                            | PTC (CLN)                       | Intermediate                     | 900             | 41                |                      |
| 15             | 32               | Male   | 7.14                            | PTC (CLN)                       | Intermediate                     | 750             | 82                |                      |
| 16             | 53               | Male   | 4.6                             | FTC (bone)                      | High                             | 800             | 151               |                      |

PTC: Papillary thyroid carcinoma, FTC: Follicular cell carcinoma, RAI: Radioactive iodine, CLN: Cervical lymph node

**Table 3: Univariate and multivariate analyses of significant prognostic factors for remission cases (n=16)**

| Characteristics | Remission, n (%) | Nonremission, n (%) | P | ORs (95% CI) | P | ORs (95% CI) | P |
|-----------------|------------------|---------------------|---|--------------|---|--------------|---|
| Age (years), mean±SD | 41.1±16.5 | 43.4±17.9 | 0.62 | Reference | Reference | 0.96 | 0.25-3.67 | 0.96 |
| Gender | Female | 11 (9.5) | 105 (90.5) | 0.00 | Reference | Reference | 1.07 | 0.30-3.83 | 0.92 |
| RAIU (%), mean±SD | 3.5±2.4 | 5.2±5.6 | 0.24 | Reference | Reference | 2.33 | 0.55-9.77 | 0.25 |
| Cell type | PTC | 12 (8.8) | 125 (91.2) | 0.96 | Reference | Reference | 2.59 | 0.33-20.51 | 0.37 |
| Others | 3 (10.0) | 26 (89.7) | 1.20 | 0.32-4.56 | 0.79 | 2.59 | 0.33-20.51 | 0.37 |
| Risk of recurrence | Low | 5 (45.5) | 6 (54.5) | <0.001 | Reference | Reference | 0.91 | 0.07-11.06 | 0.94 |
| Intermediate | 10 (8.5) | 107 (91.5) | 0.11 | 0.03-0.43 | 0.002 | 0.05 | 0.01-0.49 | 0.01 |
| High | 1 (2.1) | 47 (97.9) | 0.03 | 0.00-0.26 | 0.002 | 0.01 | 0.00-0.17 | 0.003 |
| Metastasis | No | 5 (14.3) | 30 (85.7) | 0.24 | Reference | Reference | 4.45 | 0.50-39.66 | 0.18 |
| Yes | 11 (7.8) | 5 (92.2) | 0.51 | 0.16-1.57 | 0.24 | 4.45 | 0.50-39.66 | 0.18 |

OR: Odds ratio, CI: Confidence interval, SD: Standard deviation, RAIIU: Radioactive iodine uptake, PTC: Papillary thyroid carcinoma, FTC: Follicular cell carcinoma
gastric biopsy revealed NHL. Finally, he died from NHL. The second case was a 63-year-old woman with PTC and cervical LN metastasis who was found invasive ductal carcinoma of the right breast 2 years after the cumulative activity of I-131 of 600 mCi. She underwent right total mastectomy with sentinel LN biopsy and completed a session of chemotherapy. Then, she was in a complete remission of breast cancer.

**Bone marrow suppression**
At least 6 months after RAI treatment with a cumulative dose of 600 mCi, 18 cases (10.2%) were suspected of bone marrow suppression. Thirteen cases (7.4%) developed anemia, four patients (2.3%) had neutropenia, and the remaining one case (0.5%) had anemia with neutropenia.

**Anemia**
Fourteen cases had anemia after RAI treatment with a cumulative dose of 600 mCi (10 female [78.5%], mean age at diagnosis: 47.07 ± 16.99 years, mean Hb: 10.11 ± 0.83 g/ml). Eight cases were recovery after 6-month follow-up and the rest six cases had persistent anemia (mean follow-up period of 20.14 ± 9.13 months). Six cases with persistent anemia were 3 cases of grade I and 3 cases of Grade II anemia. Two cases of Grade II anemia, one was found lower gastrointestinal bleeding and one was proven of iron-deficiency anemia. The remaining four cases were not found the definite cause of persistent anemia.

**Neutropenia**
Five cases had mild neutropenia after RAI treatment with a cumulative dose of 600 mCi (4 females, mean age at diagnosis: 27 ± 4.42 years, mean ANC: 1,233.4 ± 207.63 cell/mm3). Four cases were recovery and 1 case had persistent mild neutropenia (mean follow-up period of 13.2 ± 4.96 months). The case with persistent mild neutropenia was a 27-year-old female PTC patient with cervical node, bilateral lungs, and bone metastases. She was found mild neutropenia (ANC: 1,070 cell/mm3) after receiving the fourth session of I-131 therapy (cumulative dose of 600 mCi). After 15-month follow-up, ANC was slightly increased with the level of 1400 cell/mm3 without clinical symptom. This case also had persistent Grade I anemia without a definite cause.

**Salivary gland dysfunction**
Seven cases were classified as salivary gland dysfunction. Three of seven cases had dry mouth with diagnosed as xerostomia and the rest four cases had sialadenitis. From these seven patients, three cases complained about salivary gland dysfunction before the cumulative activity of I-131 of 600 mCi (1 case after 150 mCi, 1 case after 210 mCi, and 1 case after 300 mCi). All of the seven cases had persistent symptoms.

**DISCUSSION**

The outcomes of DTC patients are excellent, with long-term disease survival rates approaching 90% over 20 years following appropriate treatment. Despite the overall excellent outcome, some DTC patients have DM with worse prognosis and are frequently unresponsive to conventional therapy requiring multiple doses of RAI therapy. One-third of the DM patients have no I-131 uptake and die because of RR. The previous study of Wassermann et al. found that patients were classified as progressive RR had a worse prognosis which could justify molecular targeted therapy. In contrast, cases of nonprogressive RR found prolonged survival times which should be managed with “wait and see.” Our study found high incidences of nonremission cases (91.9%) after RAI treatment with a cumulative dose of ≥600 mCi, and most of the cases had SD (53.4%). The previous study of Nasreen et al. revealed a higher incidence of disease-free patients (36%) and rather low incidence of nondisease-free group (35%) after receiving a cumulative dose of ≥600 mCi I-131 as compared to our study. It is possible due to different remission criteria in their study and shorter period of follow-up in our study. Another reason was that most of the patients in their study had TNM Stage I (45%) which has high chance to be in remission. Martins-Filho et al. found that disease status was positively associated with TNM stage by multiple logistic regression analysis. Patients with higher staging (III and IV), above 45 years of age, and aggressive variants have a worse prognosis, greater chances of local recurrence, and distant metastases and require higher and more RAI doses. Our study shows similar results that the mean cumulative dose in the nonremission group was significantly higher than that in the remission group.

Nonremission cases in our study reveal multiple metastatic sites including bone, lung, mediastinal, and some of locoregional metastasis. DM is associated with mortality having five times greater probability of death than patients having no metastasis or local metastasis. Although there were 73.1% of nonremission patients who have DM in our study, we were not able to evaluate the impact on overall survival since the mean follow-up time was below 10 years. A longer follow-up time is necessary in order to evaluate the impact of this information on patient management.

In the remission group, we found that the risk of recurrence at initiation was inversely associated with remission in both univariate and multivariate analyses. Between the remission and nonremission groups, mean age at diagnosis and mean 24-h I-131 uptake before RAI treatment had no statistical differences. The previous study of Liu et al. revealed
similar results that intermediate and high risks, as well as tumor Stage T3 or T4 and LN metastasis, were significantly associated with unsuccessful outcomes.[10]

In our study, remission cases with low risk of recurrence at initiation, the total body scan of all patients revealed persistent 1–2 uptake lesions at anterior neck region on planar images which were suspected of persistent thyroid remnant. Then, they received RAI treatment until a cumulative dose of ≥600 mCi. All of these lesions might be possible due to paratracheal node metastasis rather than residual thyroid remnant because most of the thyroid remnant should be destroyed by RAI ablation.[11] However, we cannot conclude this hypothesis because we did not perform single-photon emission CT/CT in all cases as routine protocol, and then, we did not have complete data. We also found that remission DTC patients with cervical node metastasis had metastatic foci of ≤2 lesions. One remission case with high risk of recurrence had only 1 metastatic focus at the left proximal femur since the first WBS. All of our findings suggested an important observation that I-131 treatment is possible effective in patients with few metastatic sites (≤2 foci) which have high chance to be in remission.

Second primary malignancy
The use of radioiodine therapy has raised concern about the potential for the development of SPM, especially in patients with a cumulative dose exceeding 600 mCi. Rubino et al. found a correlation between RAI dose and SPM (mean follow-up: 13 years).[12] In our study, we found only 2 cases (1.1%) of SPM which included 1 case of IDC of the breast and 1 case of NHL after receiving I-131 treatment with a cumulative dose exceeding 600 mCi. In the previous study of Lin et al. revealed higher results in which there were 6.1% of secondary malignancy who was treated with I-131 cumulative dose ≥600 mCi.[13] In the previous study of Nasreen et al., they also showed similar results. They reported two patients (2.78%) with SPM after receiving a cumulative dose of ≥600 mCi: one of leukemia and the other of carcinoid tumor.[8] The lower incidence of SPM in our study than that in other populations is possible from different ethnicities and different malignancy types.

The cancer, found in our study, was not commonly found in the previous study. Second primary cancers associated with RAI treatment included bone and soft-tissue, colorectal, salivary gland cancer and leukemia.[12] In the previous study, cancer of salivary glands and leukemia are close in terms of incidence risk estimates because salivary glands receive a much higher absorbed dose and greater sensitivity of bone marrow to the stochastic effects of radiation.[15] However, some studies revealed an association between thyroid cancer and breast cancer, as seen in our study.[14]

Bone marrow suppression
Bone marrow suppression may occur within 1 month of radioiodine therapy and is usually transient. Severe bone marrow suppression seldom occurs when the radiation dose to blood is <200 cGy.[15] Bone marrow suppression occurs most often in patients who have the following risks: receive a large cumulative amount of radioiodine, receive external beam therapy in addition to I-131, have large functioning tumors that produce a high concentration of I-131, and have extensive bone metastasis.[16] In our study, we found 18 patients with suspected bone marrow suppression after receiving 600 mCi of RAI treatment, of which most of them (14 cases) had anemia. Six of 14 cases had persistent anemia for at least 6-month follow-up. Many medical conditions cause anemia such as active bleeding, iron-deficiency anemia, chronic disease, or poor nutrition. Most of the anemic patients were women who have more prevalence of anemia as compared to men. Causes of anemia in women are multiple. In majority, the cause of anemia in women is the iron-deficiency type, which occurs due to deficiency of iron, resulting in impaired formation of Hb. Women suffer from chronic blood loss due to monthly menstrual cycles, which always leads to chronic anemia. In addition, it is possible due to thalassemia or chronic disease.[17] About 1% of Thai population are affected with thalassemic disease and about 30%–40% of population are carriers of at least one of abnormal gene.[18] As there is no detail, we cannot conclude the definite cause of anemia in our study. However, the anemic patients in our study did not require blood transfusion. Otherwise, several studies have demonstrated that high-dose RAI treatment associated with leukopenia and thrombocytopenia rather than anemia.[19-21]

Salivary gland dysfunction
Iodide is greatly concentrated in the thyroid gland by carrier-mediated mechanism, but similar uptake is found in other organs, including the salivary and lacrimal glands. The concentration of secreted iodide in saliva has been reported to vary from 20 to 100 times of that in a serum. Therefore, the salivary glands can receive a substantial radiation-absorbed dose from I-131 treatment.[22] Sialadenitis and xerostomia have been considered as transient side effects of radioiodine therapy. The previous study of Ko et al. demonstrated that the risk of salivary gland secretion impairment significantly increased with increasing administered doses.[23] Alexander et al. reported that 42.9% of patients undergoing radioiodine therapy suffered from reduced salivary gland function more than 1 year after the last radioiodine application and persistent xerostomia occurred in 4.4%.[21] The previous study
of Solans revealed that 32.9% of patients reported subjective xerostomia which persisted to the second year of follow-up in 20.3% of cases and was still present more than 3 years after the last dose of RAI treatment in 15.2% of cases.\textsuperscript{24} Our study found only 7 cases of permanent salivary gland dysfunction (1.7% of xerostomia and 2.2% of sialadenitis), in which the incidence is relatively low as compared to the previous studies. It is possible due to preventive protocol in our institution such as encourage patients to suck sour/lemon candies 24 h after RAI therapy and drink plenty of water during admission.

There are some limitations to our study. First, there is a relatively short follow-up period which limits the ability for overall survival analysis and because of the long latency of radiation-induced cytogenetic change to malignancy. Second, a retrospective cohort study is typically lower in statistical quality. A multicenter, international origin dataset is needed to validate our results. Third, the identification of salivary glands dysfunction using the patient’s record instead of image measurements. The information regarding whether or not patients received protection for salivary glands was not available from the database, although such protection is routinely offered during treatment in our center.

CONCLUSION

Although the complications after I-131 treatment with a cumulative dose exceeding or equal to 600 mCi in DTC patients were low and not severe, the patients with remission were in <10%. Our study suggests that the decision to administer further treatments should be made on an individual basis because beneficial effects may be controversial.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.
2. Bryan RH, Eric KA, Keith CB, Gerard MD, Susan JM, Yuri E, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2015;26:76-80.
3. Brilli L, Pacini F. Targeted therapy in refractory thyroid cancer: Current achievements and limitations. Future Oncol 2011;7:657-68.
4. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, et al. Sorafenib in metastatic thyroid cancer: A systematic review. Oncologist 2014;19:251-8.
5. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagl JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9.
6. Palme CE, Wasem Z, Raza SN, Esdi S, Walfish P, Freeman JL. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:819-24.
7. Wassermann J, Bernier M, Sano J, Lepoutre-lussey C, Buffet C, Simon J, et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist 2016;21:50-8.
8. Nasreen F, Nahar N, Sultana S, Alam F. Outcome of well-differentiated thyroid carcinoma patients receiving a cumulative doses of ≥600 mCi (22GBq) of I-131. Bangladesh J Nucl Med 2014;17:114-9.
9. Martins-Filho R, Ward LS, Amorim BJ, Santos AO, Lima MCL, Ramos CD, et al. Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: Knowing when to stop. Arq Bras Endocrinol Metabol 2010;54:807-12.
10. Liu N, Meng Z, Jia Q, Tan J, Zhang G, Zheng W, et al. Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status. Sci Rep 2016;6:34915.
11. Karam M, Gianoukakis A, Feustel PJ, Cheoma A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003;24:489-95.
12. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schwartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.
13. Lin JD, Kuo SF, Huang BY, Lin SF, Chen ST. The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. Nucl Med Commun 2018;39:1091-6.
14. Joseph KR, Edirimanne S, Eslick GD. The association between breast cancer and thyroid cancer: A meta-analysis. Breast Cancer Res Treat 2015;152:173-81.
15. Benna RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-82.
16. de Vathaire F, Schlumberger M, Delisle MJ, Francesc C, Challeton C, de la Genardiére E, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997;75:734-9.
17. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci 2019;1450:15-31.
18. Panich V, Pornpatkul M, Srirongrueng W. The problem of thalassemia in Thailand. Southeast Asian J Trop Med Public Health 1992;23 Suppl 2:1-6.
19. Molinaro E, Leboeuf R, Shue B, Martorella AJ, Fleisher M, Larson S, et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid 2009;19:1035-41.
20. Prinsen HT, Helselink EN, Brouwers AH, Plakker JT, Sluiter WJ, Links TP, et al. Bone marrow function after I-131 therapy in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2015;100;3911-7.
21. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-4.
22. Myant NB. Iodine metabolism of salivary glands. Ann N Y Acad Sci 1960;85:208-14.
23. Ko KY, Kao CH, Lin CL, Huang WS, Yen RF. I-131 treatment for thyroid cancer and long-term side effects of high-dose radioiodine therapy for thyroid carcinom. J Nucl Med 1998;39:1551-4.
24. Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O’Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738-43.